CSG Puts $2.5bn Air Defence Order on Table as Quarterly Report Tests Investor Trust

The Czechoslovak Group heads into its first quarterly earnings release since January's IPO with a major contract win to tout and a short-seller cloud to dispel. Shares of the defence company have clawed back some ground, rising 5.53% on Tuesday to €17.24, yet remain nearly 50% below the January high of €33.81 after a brutal sell-off triggered by allegations from Hunterbrook Media.

Hunterbrook struck at the heart of CSG's investment case earlier this month, arguing that the company is not a true ammunition manufacturer but rather depends on refurbishing old stockpiles. The stock shed more than 13% in a single session. Management has rejected the claims, pointing to a forensic audit that found no supporting evidence, and is weighing legal action against the short seller.

Amid that firestorm, CSG has now confirmed a sizeable order for an air defence system valued at $2.5bn, directed at a customer in Southeast Asia. That region contributed just 2.5% of group revenue last year, but the deal underscores its strategic importance as a growth market. The company also used the opportunity to clear up an old rumour: a planned entry into Vývoj Martin in 2021 never materialised, and the purchase agreement was dissolved without any payment flowing.

The Q1 report due on 20 May will be the first since the group went public in January and the first to reflect costs linked to the listing. Investors are looking for hard data on production volumes, capacity utilisation and order quality rather than top-line numbers alone. Operational momentum appears solid on the surface: last year CSG posted revenue of €6.74bn and adjusted EBIT of €1.6bn, a margin of 24.1%. For the current year management has guided for revenue of €7.4bn to €7.6bn and an adjusted EBIT margin between 24% and 25%.

Should investors sell immediately? Or is it worth buying CSG?

Capacity expansion is central to the narrative. New production lines in Slovakia will add 70,000 rounds of ammunition annually, and the group aims to increase total capacity by 20% by the end of 2026. Its medium-term target is 1.1 million rounds per year, drawing on facilities in Slovakia, Greece, Serbia, Spain and India. On the cash side, CSG has already collected €275m from the divestment of its Mobility, Perazzi and Healthcare units, providing a buffer for investment.

Credit agencies have lent support. Moody's raised the secured senior debt rating to Baa3 in February, granting investment-grade status, while Fitch maintains a BBB- with stable outlook. Moody's expects normalised free cash flow of €500m to €700m annually, which would help fund the capacity build-out at lower financing costs.

Analysts have largely held their ground. The nine covering the stock all carry buy recommendations, with a consensus price target of €35.40 and a high estimate of €42. At a price-to-earnings ratio of roughly 24, CSG trades at a discount to the sector average of almost 31 — a valuation gap the company will hope to close with convincing operational evidence.

CSG at a turning point? This analysis reveals what investors need to know now.

The order book stands at €15bn across all segments, with an additional pipeline of €27bn, though CSG distinguishes between firm commitments and negotiations. The combined €42bn figure often cited blends different levels of certainty, and the upcoming report will need to clarify that split. Wednesday's release will therefore be judged not just on revenue and profit, but on the granularity of production data, capacity milestones and cash flow detail. Only if those numbers match the strong guidance can the company begin to rebuild the trust that the short-seller attack has eroded.

Ad

CSG Stock: New Analysis - 19 May

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | CSG | boerse | 69375018 |